Image testing based on biomedical drug loading in cardiovascular drug care simulation for coronary heart disease.

Coronary heart disease is a common cardiovascular disease, and its therapeutic effect is affected by the distribution and absorption of drugs in the body. Biomedical drug-carrying image testing technology can provide a quantitative assessment of drug distribution and absorption in the body. This study aims to explore the application of biomedical drug-carrying image testing technology in the simulation of cardiovascular drug care in coronary heart disease, so as to provide reference for the optimization of drug treatment plan and individualized treatment. The study collected clinical data and medication regiments of patients with coronary heart disease. Then, the imaging examination of patients was carried out by selecting appropriate drug loading markers using the biomedical drug loading image examination technology. Then quantitative analysis was used to process the image data to quantitatively evaluate the distribution and absorption of drugs in the cardiovascular system. The quantitative data of drug distribution and absorption in patients with coronary heart disease have been obtained successfully by means of biomedical imaging. These data reveal the dynamic changes of drugs in the cardiovascular system, and help doctors optimize drug therapy, improve treatment effectiveness, and achieve personalized treatment.

Methylation of the miR­29b­3p promoter contributes to angiogenesis, invasion, and migration in pancreatic cancer.

The aim of the present study was to investigate the effects of microRNA (miR)­29b­3p gene promoter methylation on angiogenesis, invasion, and migration in human pancreatic cancer. Prediction of promoter methylation of miR­29b­3p was performed through the MethPrimer tool. Then the methylation levels of miR­29b­3p in human pancreatic cancer tissues and cell lines were detected by pyrosequencing, and the relative expression of miR­29b­3p was assessed in pancreatic cancer tissues by qPCR. The results were analyzed by linear regression. Western blot analysis was used to detect expression of DNA methyltransferases (DNMTs) in pancreatic cancer tissues and adjacent tissues. The Transwell assay was used to detect the ability of cell migration and invasion. Cells were co­cultured with human umbilical vein endothelial cells (HUVECs) to detect the ability of angiogenesis. The results revealed that DNMT1 expression in pancreatic cancer tissues was higher than that in adjacent tissues. Further results showed that expression of miR­29b was negatively correlated with the methylation level of the miR­29b promoter. Bxpc3 and Capan­2 cells had higher methylation levels, and the expression level of miR­29b­3p in Bxpc3 and Capan­2 cells was found to be lower than that of other cell lines. Expression of zonula occludens­1 (ZO­1) and occludin was significantly increased, and the migration of cancer cells was decreased after cells were treated with siRNA DNMT1. Further results showed that miR­29b reversed the promotive effect of DNMT1 overexpression on tumor cell malignant properties. Methylation of the miR­29b­3p promoter contributes to angiogenesis, invasion, and migration in pancreatic cancer. This study indicated that the alteration of methylation of mR­19b may be a potential approach for inhibiting the progression of pancreatic cancer.